gip/glp 1-agonist tirzepatide The Novel Dual GIP and GLP‐1 Receptor Agonist Attenuates Colon Cancer Development by Regulating Glucose Metabolism - Zhang - 2025 - Advanced Science New Weight-Loss Drugs Are Poised
Description
Obes Sci Pract (2017) 3:314
As the newest weight-loss drug on the scene, retatrutide targets three receptors: GLP-1, GIP and glucagon
Diabetes Atlas, 10th edn
*Correspondence: Fuer Lu, [email protected]
doi: 10.1016/j.celrep.2019.01.047
Studies have shown that these medications can reduce the risk of heart attacks, strokes, kidney disease, obstructive sleep apnea and now possibly cancer
